Lanean...
15 years journey of idiopathic pulmonary arterial hypertension with BMPR2 mutation
Pulmonary arterial hypertension (PAH) is known as one of diseases with the worst prognosis. Recently, targeted PAH drugs have been developed and approved for use; therefore, the treatment strategy and goals have changed, and the prognosis has improved over two decades. We reviewed the case of a fema...
Gorde:
| Argitaratua izan da: | Clin Hypertens |
|---|---|
| Egile Nagusiak: | , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
BioMed Central
2019
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6771102/ https://ncbi.nlm.nih.gov/pubmed/31583114 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40885-019-0127-7 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|